pandem
trigger
worldwid
health
disast
main
proteas
attract
drug
target
among
coronavirus
due
vital
role
process
polyprotein
translat
viral
rna
present
exact
drug
treatment
diseas
caus
present
studi
report
potenti
inhibitori
activ
fda
approv
drug
main
proteas
molecular
dock
studi
investig
bind
affin
proteas
activ
site
dock
studi
reveal
drug
oseltamivir
drug
rifampin
antitb
drug
maraviroc
etravirin
indinavir
rilpivirin
antihiv
drug
atovaquon
quinidin
halofantrin
amodiaquin
tetracylcin
azithromycin
hydroxycholoroquin
antimalari
drug
among
other
bind
activ
site
proteas
similar
higher
affin
howev
insilico
abil
drug
molecul
test
studi
need
valid
carri
vitro
vivo
studi
moreov
studi
spread
potenti
use
current
drug
consid
use
compris
fast
expand
infect
new
occur
human
coronaviru
inform
decemb
wuhan
china
afterward
underway
spread
across
world
put
whole
world
high
attent
world
health
organ
surveil
draft
januari
state
travel
wuhan
hubei
provinc
china
two
week
earlier
onset
sign
suppos
case
april
st
total
confirm
infect
report
worldwid
death
increas
mortal
rate
world
health
organ
strategi
compris
distribut
includ
decreas
humantohuman
dispers
prevent
interact
individu
accordingli
avoid
transmiss
extens
event
interact
critic
risk
evid
popul
india
first
case
report
kerala
januari
april
case
death
report
ministri
health
famili
welfar
govern
india
member
betacoronavirus
similar
sever
acut
respiratori
syndrom
human
coronaviru
sar
hcov
also
middleeast
respiratori
syndrom
human
coronaviru
mer
hcov
main
proteas
mpro
one
greatestcharacter
drug
target
among
coronavirus
besid
papainlik
proteas
main
proteas
enzym
vital
process
polyprotein
translat
viral
rna
crucial
function
main
proteas
viru
duplic
make
enzym
capabl
target
expans
inhibitor
possibl
treatment
remedi
infect
novel
coronaviru
date
precis
therapeut
medicin
vaccin
accept
manag
human
coronaviru
clinic
trial
describ
antihiv
drug
chloroquin
phosphat
antimalari
drug
assur
therapeut
effect
specif
chloroquin
phosphat
suggest
treat
relat
pneumonia
larger
inhabit
futur
subsequ
clinic
trial
suggest
hydroxychloroquin
supplementari
azithromycin
oper
manag
encourag
us
accomplish
systemat
studi
clinic
approv
medicin
use
molecular
dock
reinvestig
biolog
efficaci
pharmacolog
properti
howev
organ
studi
inhibit
coronaviru
clinic
approv
drug
best
knowledg
henc
present
studi
aim
molecular
dock
studi
clinic
approv
drug
main
proteas
molecular
dock
autodock
softwar
use
free
energi
dg
bind
viral
proteas
select
fda
approv
drug
creat
mean
molecular
dock
packag
dock
comput
simul
method
ligand
bind
receptor
enzym
expect
favor
orient
bind
one
molecul
second
form
steadi
complex
predict
attract
activ
bind
minor
molecul
enzym
target
use
score
function
dock
use
therefor
dock
show
signific
role
ration
design
medicin
sensit
dock
calcul
concern
geometri
involv
ligand
display
even
minor
chang
ligand
structur
lead
big
chang
geometri
score
subsequ
dock
pose
antivir
antimalari
medic
recogn
potenti
coronaviru
inhibitor
divers
literatur
evalu
total
fda
approv
drug
select
molecular
dock
main
proteas
among
approv
drug
drug
drug
antitb
drug
drug
antimalari
drug
select
pubchem
databas
threedimension
structur
file
select
fda
approv
drug
download
sdf
format
pubchem
use
molecular
dock
molecular
structur
select
fda
approv
drug
shown
tabl
zanamivir
isoniazid
antitb
meanwhil
proteas
crystal
structur
state
signifi
pharmacolog
target
progress
new
medicin
treatment
divers
infecti
diseas
prepar
target
enzym
autodock
tool
softwar
intric
addit
atom
enzym
step
essenti
accur
calcul
fraction
atom
charg
ligand
water
molecul
detach
make
structur
dock
gasteig
charg
consid
atom
protein
autodock
instead
kollman
charg
use
earlier
version
packag
ligand
conform
incis
take
lamarckiangenet
algorithm
lga
mixtur
genet
algorithm
nativ
search
algorithm
algorithm
initi
build
popul
entiti
divers
casual
conform
dock
enzym
distinct
protein
mutat
attain
slightli
divers
translat
altern
local
search
algorithm
achiev
energi
minim
userspecifi
amount
popul
individu
entiti
low
subsequ
energi
move
succeed
gener
procedur
repetit
algorithm
call
lamarckian
everi
novel
group
entiti
allow
receiv
local
search
variat
parent
get
mani
dock
structur
autodock
run
numer
time
use
examin
expect
dock
energi
rapid
energi
assess
attain
precalcul
nuclear
affin
capac
everi
atom
compound
molecul
bind
site
target
enzym
molecul
autogrid
process
design
pattern
found
ligandbind
pocket
autodock
tool
deliv
variou
approach
examin
outcom
dockingsimul
structur
resembl
limit
like
intermolecular
energi
visual
bind
site
energi
inhibit
constant
energi
interact
everi
atom
ligand
met
ligand
best
postur
made
score
use
autodock
score
purpos
comput
approach
drug
discoveri
develop
proven
effect
time
effici
base
difficult
labori
work
proteinligand
dock
elucid
mechan
inhibit
along
specif
effici
ligand
inhibitor
associ
drug
candid
ligand
target
receptor
fundament
bind
reaction
aim
computeraid
drug
discoveri
find
small
molecul
strong
inhibitori
activ
action
biolog
target
strength
inhibit
activ
elucid
bind
affin
oseltamivir
zanamivir
two
fda
approv
drug
dock
main
proteas
obtain
bind
energi
kcalmol
kcalmol
respect
figur
result
identifi
oseltamivir
potenti
inhibitor
main
proteas
earlier
one
studi
report
oseltamivir
prodrug
oseltamivir
carboxyl
potent
select
inhibitor
neuraminidas
glycoprotein
essenti
replic
influenza
b
virus
bind
energi
kcalmol
interact
residu
form
bond
isoniazid
rifampin
ethambutol
pyrazinamid
clinic
approv
drug
dock
bind
energi
kcalmol
respect
proteas
twentyfour
fda
approv
antihiv
drug
dock
proteas
among
twenti
four
drug
four
drug
maraviroc
etravirin
indinavir
rilpivirin
show
potenti
inhibitor
main
proteas
bind
affin
kcalmol
respect
figur
joint
research
team
shanghai
institut
materia
medica
shanghai
tech
univers
perform
drug
screen
silicon
enzym
activ
test
report
antihiv
agent
potenti
antivir
activ
januari
proteas
antihiv
drug
maraviroc
etravirin
b
indinavir
c
rilpivirin
c
indinavir
seventeen
clinic
approv
antimalari
drug
dock
proteas
seventeen
seven
drug
show
potenti
inhibitor
main
proteas
figur
residu
play
import
role
proteinligand
interact
may
serv
biomark
drug
discoveri
process
studi
focus
identif
potenti
inhibitor
corona
viru
control
viral
replic
outcom
silico
molecular
dock
studi
maintain
great
inhibitori
efficaci
one
drug
oseltamivir
one
antitb
drug
rifampin
four
antihiv
drug
maraviroc
etravirin
indinavir
rilpivirin
seven
antimalari
drug
atovaquon
quinidin
halofantrin
amodiaquin
tetracylcin
azithromycin
hydroxycholoroquin
sinc
could
launch
bond
differ
amino
acid
residu
caus
inhibit
proteas
activ
higher
bind
affin
rang
kcalmol
thu
project
bind
interact
dynam
molecul
proteas
dock
studi
evid
establish
inhibitori
strength
toward
catalyt
respons
proteas
studi
provid
support
repurpos
drug
may
help
treatment
novel
coronaviru
diseas
serv
potenti
drug
candid
curb
ongo
ever
enlarg
pandem
sinc
drug
use
studi
known
pharmacokinet
standard
approv
fda
human
use
need
undergo
specif
long
term
clinic
trial
therefor
fasten
process
therapeut
develop
coronaviru
fit
set
virus
contamin
vertebr
anim
human
slaughter
thousand
individu
around
world
growth
mortal
rate
singl
day
digest
central
nervou
system
liver
respiratori
system
human
animla
hamper
viru
infect
studi
focus
fda
approv
drug
main
proteas
coronaviru
possibl
benefici
target
manag
coronaviru
pdb
id
major
proteas
reloc
structur
pdb
newli
avail
everybodi
world
figur
proteolyt
matur
viru
proteas
precis
signific
proteas
studi
possibl
target
avoid
extent
contamin
inhibit
viral
polyprotein
cleavag
via
block
activ
site
protein
new
find
proteas
assembl
provid
enorm
chanc
recogn
possibl
drug
candid
manag
coronaviru
studi
appli
comput
approach
fda
approv
drug
order
find
specif
therapeut
possibl
agent
select
fda
approv
antivir
antitb
antivir
drug
retriv
directli
pubchem
nation
librari
medicin
molecular
dock
accomplish
drug
structur
molecular
dock
comput
techniqu
aim
find
noncoval
bind
among
protein
receptor
ligandinhibitor
small
molecul
recogn
bind
site
dock
expect
method
interact
among
target
protein
ligand
bind
energi
propos
attract
exact
ligand
asset
ligand
interact
bind
pocket
target
protein
drug
lesser
bind
energi
chosen
probabl
drug
candid
order
recogn
effect
activ
antivir
drug
fda
approv
antivir
compound
select
perform
molecular
dock
dock
result
proteas
select
drug
select
show
best
dock
score
found
best
molecul
target
site
protein
present
studi
conclud
thirteen
clinic
approv
drug
identifi
potent
inhibitor
proteas
activ
outcom
afford
strong
foundat
use
drug
corona
manag
moreov
dynam
ligand
inhibit
catalyt
respons
proteas
block
residu
amino
acid
intric
process
strand
transmiss
reaction
interact
structur
model
proteas
activ
site
afford
valuabl
guid
addit
strategi
structurebas
medicin
develop
new
oper
inhibitor
proteas
therefor
effect
inhibitor
reveal
vitro
vivo
analysi
termin
intracellular
replic
corona
viru
prior
use
drug
human
